​

HilleVax Stock (NASDAQ:HLVX)

ForecastRevenueOwnershipFinancialsChart
HilleVax by TradingView

Previous Close

$1.95

52W Range

$1.55 - $20.22

50D Avg

$1.88

200D Avg

$7.32

Market Cap

$94.63M

Avg Vol (3M)

$191.69K

Beta

0.77

Div Yield

-

HLVX Company Profile

HilleVax, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel vaccines. It is developing HIL-214, a virus-like particle-based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection. The company is headquartered in Boston, Massachusetts.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

90

IPO Date

Apr 29, 2022

Website

HLVX Performance

HLVX Financial Summary

Dec 23Dec 22Dec 21
Revenue---
Operating Income$-133.34M$-65.11M$-53.43M
Net Income$-123.57M$-257.00M$-85.03M
EBITDA$-133.34M$-60.11M$-35.99M
Basic EPS-$-9.47$-5.22
Diluted EPS-$-9.47$-5.22

Fiscal year ends in Dec 23 | Currency in USD

Peer Comparison

TickerCompany
VIGLVigil Neuroscience, Inc.
PMVPPMV Pharmaceuticals, Inc.
CGEMCullinan Oncology, Inc.
CNTACentessa Pharmaceuticals plc
MLYSMineralys Therapeutics, Inc.
EWTXEdgewise Therapeutics, Inc.
IPSCCentury Therapeutics, Inc.
STROSutro Biopharma, Inc.
CSBRChampions Oncology, Inc.
TRDAEntrada Therapeutics, Inc.
CCCCC4 Therapeutics, Inc.
GLUEMonte Rosa Therapeutics, Inc.
MNOVMediciNova, Inc.
PHVSPharvaris N.V.
PEPGPepGen Inc.
MOLNMolecular Partners AG
OPTOpthea Limited
STTKShattuck Labs, Inc.